EUROPRACTICE Leads the Way in Microchip Design

Helped by more than EUR 7 million of Sixth Framework Programme (FP6) and Seventh Framework Programme (FP7) funding, the EUROPRACTICE IC3 and EUROPRACTICE IC4 projects have produced state-of-the-art micromechanical and microelectronic technologies that are being used in universities and industry worldwide to create microchip applications for uses ranging from space technology to medical diagnostics. Using a single wafer for a range of microelectronic systems means low costs and a construction that is as simple and accessible as possible.

A simple idea to install multiple microelectronic or micromechanical systems on a single wafer to drastically cut high production costs is helping to keep Europe's microchip industry competitive worldwide.

The multi-project wafer (MPW) device has given universities access to state-of-the-art microchip design tools and has helped small and medium-sized enterprises (SMEs) to fabricate novel microchips. Thousands of universities and SMEs now use the EUROPRACTICE (CAD [computer aided design] and IC [integrated circuit] services for European universities and research institutes) MPW, giving European students, researchers and companies the chance to access the latest microchip design tools and fabrication techniques.

Installing multiple projects on to a single wafer can cut the cost of producing a microchip by up to 90%. With this innovation, EUROPRACTICE has enlarged European business and created the opportunity to bring hundreds of new microelectronic and micromechanical applications on to the market every year.

Carl Das, project manager at Belgian nanotechnology company IMEC, which coordinates EUROPRACTICE, says, "The best training is to give someone the chance to design a chip, make it, measure it and verify it. In addition, if smaller companies didn't get this kind of access, their ability to innovate would be dead-ended."

Microchips can cost from EUR 50,000 to EUR 200,000, but the EUROPRACTICE MPW means costs can be kept down to around EUR 5,000 or even less. Costs are low enough with EU funding for hundreds of EU companies and universities each year to use EUROPRACTICE to produce new products.

Researchers are provided with detailed support to make the process of microchip design as easy as possible. These include a set of design rules and software to simulate how the prototype circuit will behave. State-of-the-art tools generate an image of the final layout which then goes to a foundry where the chips are fabricated.

Carl Das says, "We do a lot of checking to make sure that the designs will function. Once we've transferred them to the foundry in 8 to 12 weeks we give our clients their chips back ready for them to measure and evaluate."

In 2008 EUROPRACTICE produced 534 application-specific integrated circuits (ASICs) of which two thirds go to European universities and research groups and the rest to customers worldwide.

Another product developed by the EUROPRACTICE consortium will be onboard the Bepi/Columbo space probe mission to Mercury scheduled for 2020: the Planetary Ion Camera or PICAM, a 3,200 x 3,200-micron mass spectrometer whose mission is to inform scientists about chemicals circulating near Mercury.

EUROPRACTICE has also developed two pioneering medical procedures. VECTOR ('Versatile endoscopic capsule for gastrointestinal tumour recognition and therapy') used advanced microelectronic and micromechanical techniques to create a 'smart pill' with two electric motors that can move around inside a human body and take diagnostic pictures of anything that looks suspicious.

The consortium has also developed a type of permanent bio-electronic implant. EUROPRACTICE worked in partnership with Imperial College London, UK, and the University of Cyprus to create implants that use both micromechanical and microelectronic functions to help restore normal balance to people who suffer from ear dysfunctions.

For further information, please visit:

Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

GPT-4, Google Gemini Fall Short in Breas…

Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports classification that could have a negative effect on patient management, according to a new international...

ChatGPT fails at heart risk assessment

Despite ChatGPT's reported ability to pass medical exams, new research indicates it would be unwise to rely on it for some health assessments, such as whether a patient with chest...

Study Shows ChatGPT Failed when Challeng…

With artificial intelligence (AI) poised to become a fundamental part of clinical research and decision making, many still question the accuracy of ChatGPT, a sophisticated AI language model, to support...

Virtual Reality Shows Promise in Fightin…

A new study published in JMIR Mental Health sheds light on the promising role of virtual reality (VR) in treating major depressive disorder (MDD). Titled "Examining the Efficacy of Extended...

AXREM and Highland Marketing Partner to …

AXREM represents member companies that collectively provide UK hospitals with most of their diagnostic medical imaging technology, and radiotherapy equipment. The association has seen substantial growth in recent years, with membership...